Medscape Medical News, May 16, 2019 Alert European Commission OKs Dupilumab for Severe Asthma Dupilumab is for patients with moderate-to-severe asthma and increased blood eosinophil and/or raised ...

The following is a summary of “Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging ...

Mild asthma attacks may last a few minutes, while moderate to severe asthma attacks can last for hours or days. Early Warning Signs of an Asthma Attack Asthma attacks sometimes begin with subtle ...

Chime Biologics is committed to enabling Mabgeek in its strategic entry into the U.S. market and will continue to provide comprehensive CMC and regulatory support for the start of the Phase III ...

An asthma attack is an episode where you experience a worsening of asthma symptoms. Asthma is a chronic lung disease that causes inflamed and narrowed airways, making breathing difficult.

The SARS-CoV-2 pandemic interrupted much respiratory research. Respiratory clinical academics joined colleagues in providing clinical care, and global research efforts were directed to finding new ...

The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for bullous pemphigoid by June 20, 2025.

Dupixent is considered the main competitor, as it is approved for moderate and severe asthma patients, but showed limited activity in severe asthma patients with low eosinophil levels. AZ and ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...